Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2026
Event: Entry into a Material Definitive Agreement (Merger Agreement) with Indivior Pharmaceuticals Inc.
Key Financial Metrics and Transaction Terms
- Transaction Structure: Merger of equals where Supernus becomes a wholly-owned subsidiary of Indivior. The combined entity will be renamed "Supernus, Inc."
- Exchange Ratio: 1.5401 Indivior shares for each Supernus share (fixed ratio).
- Post-Merger Ownership: Indivior stockholders ~56.5%; Supernus stockholders ~43.5% (fully diluted basis).
- Special Dividend: Indivior to declare a $1,000,000,000 cash dividend to its shareholders prior to the Effective Time.
- Financing: Citibank, N.A. committed to a $650 million senior secured term loan facility to fund the Special Dividend.
- Termination Fees: $101 million payable by Supernus; $174 million payable by Indivior under specified circumstances.
Material Changes and Management Commentary
This filing represents a material change in corporate structure and strategy. The transaction is described as a strategic combination intended to create a leading specialty pharmaceutical company. Key management changes include:
- CEO: Jack A. Khattar (current Supernus CEO) will serve as CEO of the Combined Company.
- CFO: Timonthy C. Dec (current Supernus CFO) will serve as CFO of the Combined Company.
- Board Composition: The Combined Company Board will consist of eight members (four nominees from Indivior, four from Supernus). The Chair will be an Indivior nominee.
- CEO Compensation: Jack A. Khattar entered a new employment agreement contingent on the merger, providing a base salary of $1,115,000 and a target annual cash bonus of 100% of base salary.
Guidance, Risks, and Contingencies
Conditions to Closing: The merger is subject to customary conditions, including stockholder approval from both companies, expiration of the HSR Act waiting period, effectiveness of the Form S-4 registration statement, and Nasdaq listing approval.
Risks and Contingencies:
- Regulatory and Approval Risk: Failure to obtain required stockholder or regulatory approvals could terminate the deal.
- Financing Risk: Closing is contingent on the funding of the $650 million term loan.
- Market Risk: The fixed exchange ratio does not adjust for market price fluctuations between signing and closing.
- Integration Risk: Potential business disruption, diversion of management attention, and failure to realize anticipated synergies.
- Tax Risk: The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code, but there is no assurance this will be achieved.
Investor Verification Checklist
- Verify the final terms and conditions in the upcoming Joint Proxy Statement/Prospectus (Form S-4).
- Confirm the status of the $650 million financing commitment from Citibank, N.A.
- Monitor the timeline for stockholder meetings and the receipt of required approvals from both Supernus and Indivior shareholders.
- Review the specific details of the $1 billion Special Dividend and its impact on Indivior's liquidity.
- Assess the potential for a "superior proposal" given the fiduciary out provisions in the Merger Agreement.